secwatch.observer — SEC 8-K summary
======================================

Issuer:     bluebird bio, Inc. (—)
CIK:        0001293971
Form:       8-K
Filed at:   2024-09-24T23:59:59+00:00
Accession:  0001293971-24-000046
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 2.05, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

bluebird bio cuts workforce 25%, targets 20% opex reduction and cash flow break-even in H2 2025
--------------------------------------------------------------------------------

- Restructuring reduces headcount by ~25% and cash operating expenses by ~20% when fully realized in Q3 2025.
- One-time cash charges of ~$3.7M for severance; stock-based compensation of $0.3M-$0.5M; most recorded in Q3 2024.
- Cash flow break-even target in H2 2025 requires ~40 drug product deliveries per quarter and additional capital.
- Year-to-date 41 patient starts; expects ~40 patient starts in Q4 2024 across three approved gene therapies.
- Restructuring substantially complete by Q1 2025; savings fully realized Q3 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1293971/000129397124000046/0001293971-24-000046-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1293971/000129397124000046/blue-20240923.htm
  HTML page:      https://secwatch.observer/filing/0001293971-24-000046

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer